Endo International has high hopes of becoming a major player in hybrid 505(b)(2) drugs in the US hospital market as it seeks to diversify away from high-competition retail generics. Initial launches from a development alliance with Nevakar are scheduled to reach the US market late next year.
“Our steriles strategy is going to be focused on hard-to-make injectables,” explained. Endo’s president and CEO, Paul Campanelli. “I know...








